REALISE Guidance Document for Asia Open for Feedback


The REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group is pleased to open the feedback consultation period for our report on: Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia.


A collaboration between global experts and 11 Asian health systems, the group has developed non-binding guidance to provide a framework to generate and use real-world data (RWD) / real-world evidence (RWE) in a consistent and efficient manner for drug reimbursement decision-making in Asia. The document focuses on drug assessments and the use of RWD/RWE as complementary evidence to randomized controlled trials (RCTs), the current gold standard for generating evidence on treatment efficacy.


The Saw Swee Hock School of Public Health (NUS, Singapore) and the Health Intervention and Technology Assessment Program (HITAP, Thailand) lead this project with the support of the International Decision Support Initiative (iDSI) and the Bill and Melinda Gates Foundation.


This feedback consultation period from October 1st to 14th (by 23:59 SGT) is intended to assess the structure, content, and usefulness of the guidance document in order to improve it for you and other users in the future.


We thank you in advance for your time and support in the development of this work. The questionnaire will take a maximum of 20 minutes to answer and your contribution will be acknowledged in the document as a small gesture of our appreciation in making this happen.


To participate, please click here.


For information and clarifications, please email:


For adding comments please sign up or log in